Modalis Therapeutics Corp. engages in the development of gene therapy drugs. It uses CRISPR-GNDM, a gene modulation technology that assists patients fighting with genetic disorders. The company was founded by Haruhiko Morita and Osamu Nureki in January 2016 and is headquartered in Tokyo, Japan.